Skip to main content
ANTHEM · Health Care · 2026-08-07

Anthem Biosciences Ltd

6.9★★ GoodStrong +7.1Stage 2 · wk 12In scan: Breakout WatchMARKET: BULL TOPPING · 2026-08-07
₹841
+1.86% today
₹47,240 Cr · Large cap
About this companyHealth Care· Biotechnology
Expand ▾

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry. It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lactobacillus species, bifidobacterium species, streptococcus species and saccharomyces boulardii; enzymes; peptides, including semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide; nutritional actives, vitamin analogues, and APIs. The company was incorporated in 2006 and is based in Bengaluru, India.

Visit company website →
P/E (TTM)
72.6
Forward 48.3
Earnings Growth (YoY)
+127.2%
Revenue +26.4%
ROE
+21.7%
Profit margin +27.9%
Dividend Yield
0.26%
P/B 14.0
vs 52W High
-2.7%
₹592.4 lo₹864.5 hi
2.7% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 12
1w13w26w
Week 12 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
18.8%
200 DMA: ₹708.1 · sloping down
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.68x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗ ⇈
Accelerating · MA20 +2.9% vs MA50 +0.5% / 10d
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
This stock ranks #49 of 79 Stage 2 stocks in Health Care by RS.
Industry
Biotechnology
↓ Peaking
Stage 2%
71.4%
20d Δ
-14.3pp
1M return
+5.3%
3M return
+11.5%
Industry Stage-2 % · last 20 days
Ranks #3 of 5 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2025-07-21 → 2026-08-07
S? 42w
S2 11w
2025-07-212026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w → S1 1w → S2 11w current
Total tracked: 55 weeks across 3 stage runs.
1M
+11.8%
3M
+7.2%
6M
+41.9%
YTD
+31.1%
1Y
+9.1%
Scan Membership
Breakout Watch
Latest: 2026-05-20
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-07S2
Wk 12 · Vol x
2026-08-06S2
Wk 11 · Vol x
2026-08-05S2
Wk 11 · Vol x
2026-08-04S2
Wk 11 · Vol x
2026-08-03S2
Wk 11 · Vol x
2026-07-31S2
Wk 11 · Vol x
2026-07-30S2
Wk 10 · Vol x
2026-07-29S2
Wk 10 · Vol x
2026-07-28S2
Wk 10 · Vol x
2026-07-27S2
Wk 10 · Vol x
2026-07-24S2
Wk 10 · Vol x
2026-07-23S2
Wk 9 · Vol x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹776.5
200 DMA
₹708.1
52W High
₹864.5
52W Low
₹592.4
5D Low
₹819.3
Resistance levels (recent highs)
20d High
₹841
60d High
₹841
120d High
₹841
250d High
₹864.5
Next resistance
+2.8%
to 250d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.